Global Granulomatosis with Polyangiitis Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Granulomatosis with Polyangiitis Drug market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Granulomatosis with Polyangiitis Drug industry chain, the market status of Hospital (Benralizumab, Avacopan), Clinic (Benralizumab, Avacopan), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Granulomatosis with Polyangiitis Drug.
Regionally, the report analyzes the Granulomatosis with Polyangiitis Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Granulomatosis with Polyangiitis Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Granulomatosis with Polyangiitis Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Granulomatosis with Polyangiitis Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Pcs), revenue generated, and market share of different by Type (e.g., Benralizumab, Avacopan).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Granulomatosis with Polyangiitis Drug market.
Regional Analysis: The report involves examining the Granulomatosis with Polyangiitis Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Granulomatosis with Polyangiitis Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Granulomatosis with Polyangiitis Drug:
Company Analysis: Report covers individual Granulomatosis with Polyangiitis Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Granulomatosis with Polyangiitis Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
Technology Analysis: Report covers specific technologies relevant to Granulomatosis with Polyangiitis Drug. It assesses the current state, advancements, and potential future developments in Granulomatosis with Polyangiitis Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Granulomatosis with Polyangiitis Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Granulomatosis with Polyangiitis Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe Granulomatosis with Polyangiitis Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Granulomatosis with Polyangiitis Drug, with price, sales, revenue and global market share of Granulomatosis with Polyangiitis Drug from 2019 to 2024.
Chapter 3, the Granulomatosis with Polyangiitis Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Granulomatosis with Polyangiitis Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Granulomatosis with Polyangiitis Drug market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Granulomatosis with Polyangiitis Drug.
Chapter 14 and 15, to describe Granulomatosis with Polyangiitis Drug sales channel, distributors, customers, research findings and conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Granulomatosis with Polyangiitis Drug industry chain, the market status of Hospital (Benralizumab, Avacopan), Clinic (Benralizumab, Avacopan), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Granulomatosis with Polyangiitis Drug.
Regionally, the report analyzes the Granulomatosis with Polyangiitis Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Granulomatosis with Polyangiitis Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Granulomatosis with Polyangiitis Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Granulomatosis with Polyangiitis Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Pcs), revenue generated, and market share of different by Type (e.g., Benralizumab, Avacopan).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Granulomatosis with Polyangiitis Drug market.
Regional Analysis: The report involves examining the Granulomatosis with Polyangiitis Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Granulomatosis with Polyangiitis Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Granulomatosis with Polyangiitis Drug:
Company Analysis: Report covers individual Granulomatosis with Polyangiitis Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Granulomatosis with Polyangiitis Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
Technology Analysis: Report covers specific technologies relevant to Granulomatosis with Polyangiitis Drug. It assesses the current state, advancements, and potential future developments in Granulomatosis with Polyangiitis Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Granulomatosis with Polyangiitis Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Granulomatosis with Polyangiitis Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- Benralizumab
- Avacopan
- Rituximab Biosimilar
- Others
- Hospital
- Clinic
- Others
- Bionovis SA
- Bristol-Myers Squibb Company
- ChemoCentryx Inc
- Coherus BioSciences Inc
- Genor BioPharma Co Ltd
- GlaxoSmithKline Plc
- Iltoo Pharma
- Panacea Biotec Ltd
- Sandoz International GmbH
- The International Biotechnology Center (IBC) Generium
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Granulomatosis with Polyangiitis Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Granulomatosis with Polyangiitis Drug, with price, sales, revenue and global market share of Granulomatosis with Polyangiitis Drug from 2019 to 2024.
Chapter 3, the Granulomatosis with Polyangiitis Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Granulomatosis with Polyangiitis Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Granulomatosis with Polyangiitis Drug market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Granulomatosis with Polyangiitis Drug.
Chapter 14 and 15, to describe Granulomatosis with Polyangiitis Drug sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Granulomatosis with Polyangiitis Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Granulomatosis with Polyangiitis Drug Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Benralizumab
1.3.3 Avacopan
1.3.4 Rituximab Biosimilar
1.3.5 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Granulomatosis with Polyangiitis Drug Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Granulomatosis with Polyangiitis Drug Market Size & Forecast
1.5.1 Global Granulomatosis with Polyangiitis Drug Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Granulomatosis with Polyangiitis Drug Sales Quantity (2019-2030)
1.5.3 Global Granulomatosis with Polyangiitis Drug Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Bionovis SA
2.1.1 Bionovis SA Details
2.1.2 Bionovis SA Major Business
2.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Product and Services
2.1.4 Bionovis SA Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Bionovis SA Recent Developments/Updates
2.2 Bristol-Myers Squibb Company
2.2.1 Bristol-Myers Squibb Company Details
2.2.2 Bristol-Myers Squibb Company Major Business
2.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product and Services
2.2.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
2.3 ChemoCentryx Inc
2.3.1 ChemoCentryx Inc Details
2.3.2 ChemoCentryx Inc Major Business
2.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product and Services
2.3.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 ChemoCentryx Inc Recent Developments/Updates
2.4 Coherus BioSciences Inc
2.4.1 Coherus BioSciences Inc Details
2.4.2 Coherus BioSciences Inc Major Business
2.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product and Services
2.4.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Coherus BioSciences Inc Recent Developments/Updates
2.5 Genor BioPharma Co Ltd
2.5.1 Genor BioPharma Co Ltd Details
2.5.2 Genor BioPharma Co Ltd Major Business
2.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product and Services
2.5.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Genor BioPharma Co Ltd Recent Developments/Updates
2.6 GlaxoSmithKline Plc
2.6.1 GlaxoSmithKline Plc Details
2.6.2 GlaxoSmithKline Plc Major Business
2.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product and Services
2.6.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 GlaxoSmithKline Plc Recent Developments/Updates
2.7 Iltoo Pharma
2.7.1 Iltoo Pharma Details
2.7.2 Iltoo Pharma Major Business
2.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product and Services
2.7.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Iltoo Pharma Recent Developments/Updates
2.8 Panacea Biotec Ltd
2.8.1 Panacea Biotec Ltd Details
2.8.2 Panacea Biotec Ltd Major Business
2.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product and Services
2.8.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Panacea Biotec Ltd Recent Developments/Updates
2.9 Sandoz International GmbH
2.9.1 Sandoz International GmbH Details
2.9.2 Sandoz International GmbH Major Business
2.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product and Services
2.9.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Sandoz International GmbH Recent Developments/Updates
2.10 The International Biotechnology Center (IBC) Generium
2.10.1 The International Biotechnology Center (IBC) Generium Details
2.10.2 The International Biotechnology Center (IBC) Generium Major Business
2.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product and Services
2.10.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 The International Biotechnology Center (IBC) Generium Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: GRANULOMATOSIS WITH POLYANGIITIS DRUG BY MANUFACTURER
3.1 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Manufacturer (2019-2024)
3.2 Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturer (2019-2024)
3.3 Global Granulomatosis with Polyangiitis Drug Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Granulomatosis with Polyangiitis Drug by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Granulomatosis with Polyangiitis Drug Manufacturer Market Share in 2023
3.4.2 Top 6 Granulomatosis with Polyangiitis Drug Manufacturer Market Share in 2023
3.5 Granulomatosis with Polyangiitis Drug Market: Overall Company Footprint Analysis
3.5.1 Granulomatosis with Polyangiitis Drug Market: Region Footprint
3.5.2 Granulomatosis with Polyangiitis Drug Market: Company Product Type Footprint
3.5.3 Granulomatosis with Polyangiitis Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Granulomatosis with Polyangiitis Drug Market Size by Region
4.1.1 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2019-2030)
4.1.2 Global Granulomatosis with Polyangiitis Drug Consumption Value by Region (2019-2030)
4.1.3 Global Granulomatosis with Polyangiitis Drug Average Price by Region (2019-2030)
4.2 North America Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030)
4.3 Europe Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030)
4.4 Asia-Pacific Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030)
4.5 South America Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030)
4.6 Middle East and Africa Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2030)
5.2 Global Granulomatosis with Polyangiitis Drug Consumption Value by Type (2019-2030)
5.3 Global Granulomatosis with Polyangiitis Drug Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2030)
6.2 Global Granulomatosis with Polyangiitis Drug Consumption Value by Application (2019-2030)
6.3 Global Granulomatosis with Polyangiitis Drug Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2030)
7.2 North America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2030)
7.3 North America Granulomatosis with Polyangiitis Drug Market Size by Country
7.3.1 North America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2030)
7.3.2 North America Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2030)
8.2 Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2030)
8.3 Europe Granulomatosis with Polyangiitis Drug Market Size by Country
8.3.1 Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2030)
8.3.2 Europe Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Granulomatosis with Polyangiitis Drug Market Size by Region
9.3.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2030)
10.2 South America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2030)
10.3 South America Granulomatosis with Polyangiitis Drug Market Size by Country
10.3.1 South America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2030)
10.3.2 South America Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Granulomatosis with Polyangiitis Drug Market Size by Country
11.3.1 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Granulomatosis with Polyangiitis Drug Market Drivers
12.2 Granulomatosis with Polyangiitis Drug Market Restraints
12.3 Granulomatosis with Polyangiitis Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Granulomatosis with Polyangiitis Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Granulomatosis with Polyangiitis Drug
13.3 Granulomatosis with Polyangiitis Drug Production Process
13.4 Granulomatosis with Polyangiitis Drug Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Granulomatosis with Polyangiitis Drug Typical Distributors
14.3 Granulomatosis with Polyangiitis Drug Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Granulomatosis with Polyangiitis Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Granulomatosis with Polyangiitis Drug Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Benralizumab
1.3.3 Avacopan
1.3.4 Rituximab Biosimilar
1.3.5 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Granulomatosis with Polyangiitis Drug Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Granulomatosis with Polyangiitis Drug Market Size & Forecast
1.5.1 Global Granulomatosis with Polyangiitis Drug Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Granulomatosis with Polyangiitis Drug Sales Quantity (2019-2030)
1.5.3 Global Granulomatosis with Polyangiitis Drug Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Bionovis SA
2.1.1 Bionovis SA Details
2.1.2 Bionovis SA Major Business
2.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Product and Services
2.1.4 Bionovis SA Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Bionovis SA Recent Developments/Updates
2.2 Bristol-Myers Squibb Company
2.2.1 Bristol-Myers Squibb Company Details
2.2.2 Bristol-Myers Squibb Company Major Business
2.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product and Services
2.2.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
2.3 ChemoCentryx Inc
2.3.1 ChemoCentryx Inc Details
2.3.2 ChemoCentryx Inc Major Business
2.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product and Services
2.3.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 ChemoCentryx Inc Recent Developments/Updates
2.4 Coherus BioSciences Inc
2.4.1 Coherus BioSciences Inc Details
2.4.2 Coherus BioSciences Inc Major Business
2.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product and Services
2.4.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Coherus BioSciences Inc Recent Developments/Updates
2.5 Genor BioPharma Co Ltd
2.5.1 Genor BioPharma Co Ltd Details
2.5.2 Genor BioPharma Co Ltd Major Business
2.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product and Services
2.5.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Genor BioPharma Co Ltd Recent Developments/Updates
2.6 GlaxoSmithKline Plc
2.6.1 GlaxoSmithKline Plc Details
2.6.2 GlaxoSmithKline Plc Major Business
2.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product and Services
2.6.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 GlaxoSmithKline Plc Recent Developments/Updates
2.7 Iltoo Pharma
2.7.1 Iltoo Pharma Details
2.7.2 Iltoo Pharma Major Business
2.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product and Services
2.7.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Iltoo Pharma Recent Developments/Updates
2.8 Panacea Biotec Ltd
2.8.1 Panacea Biotec Ltd Details
2.8.2 Panacea Biotec Ltd Major Business
2.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product and Services
2.8.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Panacea Biotec Ltd Recent Developments/Updates
2.9 Sandoz International GmbH
2.9.1 Sandoz International GmbH Details
2.9.2 Sandoz International GmbH Major Business
2.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product and Services
2.9.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Sandoz International GmbH Recent Developments/Updates
2.10 The International Biotechnology Center (IBC) Generium
2.10.1 The International Biotechnology Center (IBC) Generium Details
2.10.2 The International Biotechnology Center (IBC) Generium Major Business
2.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product and Services
2.10.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 The International Biotechnology Center (IBC) Generium Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: GRANULOMATOSIS WITH POLYANGIITIS DRUG BY MANUFACTURER
3.1 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Manufacturer (2019-2024)
3.2 Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturer (2019-2024)
3.3 Global Granulomatosis with Polyangiitis Drug Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Granulomatosis with Polyangiitis Drug by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Granulomatosis with Polyangiitis Drug Manufacturer Market Share in 2023
3.4.2 Top 6 Granulomatosis with Polyangiitis Drug Manufacturer Market Share in 2023
3.5 Granulomatosis with Polyangiitis Drug Market: Overall Company Footprint Analysis
3.5.1 Granulomatosis with Polyangiitis Drug Market: Region Footprint
3.5.2 Granulomatosis with Polyangiitis Drug Market: Company Product Type Footprint
3.5.3 Granulomatosis with Polyangiitis Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Granulomatosis with Polyangiitis Drug Market Size by Region
4.1.1 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2019-2030)
4.1.2 Global Granulomatosis with Polyangiitis Drug Consumption Value by Region (2019-2030)
4.1.3 Global Granulomatosis with Polyangiitis Drug Average Price by Region (2019-2030)
4.2 North America Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030)
4.3 Europe Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030)
4.4 Asia-Pacific Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030)
4.5 South America Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030)
4.6 Middle East and Africa Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2030)
5.2 Global Granulomatosis with Polyangiitis Drug Consumption Value by Type (2019-2030)
5.3 Global Granulomatosis with Polyangiitis Drug Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2030)
6.2 Global Granulomatosis with Polyangiitis Drug Consumption Value by Application (2019-2030)
6.3 Global Granulomatosis with Polyangiitis Drug Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2030)
7.2 North America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2030)
7.3 North America Granulomatosis with Polyangiitis Drug Market Size by Country
7.3.1 North America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2030)
7.3.2 North America Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2030)
8.2 Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2030)
8.3 Europe Granulomatosis with Polyangiitis Drug Market Size by Country
8.3.1 Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2030)
8.3.2 Europe Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Granulomatosis with Polyangiitis Drug Market Size by Region
9.3.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2030)
10.2 South America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2030)
10.3 South America Granulomatosis with Polyangiitis Drug Market Size by Country
10.3.1 South America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2030)
10.3.2 South America Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Granulomatosis with Polyangiitis Drug Market Size by Country
11.3.1 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Granulomatosis with Polyangiitis Drug Market Drivers
12.2 Granulomatosis with Polyangiitis Drug Market Restraints
12.3 Granulomatosis with Polyangiitis Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Granulomatosis with Polyangiitis Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Granulomatosis with Polyangiitis Drug
13.3 Granulomatosis with Polyangiitis Drug Production Process
13.4 Granulomatosis with Polyangiitis Drug Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Granulomatosis with Polyangiitis Drug Typical Distributors
14.3 Granulomatosis with Polyangiitis Drug Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Granulomatosis with Polyangiitis Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Granulomatosis with Polyangiitis Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Bionovis SA Basic Information, Manufacturing Base and Competitors
Table 4. Bionovis SA Major Business
Table 5. Bionovis SA Granulomatosis with Polyangiitis Drug Product and Services
Table 6. Bionovis SA Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Bionovis SA Recent Developments/Updates
Table 8. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 9. Bristol-Myers Squibb Company Major Business
Table 10. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product and Services
Table 11. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Bristol-Myers Squibb Company Recent Developments/Updates
Table 13. ChemoCentryx Inc Basic Information, Manufacturing Base and Competitors
Table 14. ChemoCentryx Inc Major Business
Table 15. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product and Services
Table 16. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. ChemoCentryx Inc Recent Developments/Updates
Table 18. Coherus BioSciences Inc Basic Information, Manufacturing Base and Competitors
Table 19. Coherus BioSciences Inc Major Business
Table 20. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product and Services
Table 21. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Coherus BioSciences Inc Recent Developments/Updates
Table 23. Genor BioPharma Co Ltd Basic Information, Manufacturing Base and Competitors
Table 24. Genor BioPharma Co Ltd Major Business
Table 25. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product and Services
Table 26. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Genor BioPharma Co Ltd Recent Developments/Updates
Table 28. GlaxoSmithKline Plc Basic Information, Manufacturing Base and Competitors
Table 29. GlaxoSmithKline Plc Major Business
Table 30. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product and Services
Table 31. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. GlaxoSmithKline Plc Recent Developments/Updates
Table 33. Iltoo Pharma Basic Information, Manufacturing Base and Competitors
Table 34. Iltoo Pharma Major Business
Table 35. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product and Services
Table 36. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Iltoo Pharma Recent Developments/Updates
Table 38. Panacea Biotec Ltd Basic Information, Manufacturing Base and Competitors
Table 39. Panacea Biotec Ltd Major Business
Table 40. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product and Services
Table 41. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Panacea Biotec Ltd Recent Developments/Updates
Table 43. Sandoz International GmbH Basic Information, Manufacturing Base and Competitors
Table 44. Sandoz International GmbH Major Business
Table 45. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product and Services
Table 46. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Sandoz International GmbH Recent Developments/Updates
Table 48. The International Biotechnology Center (IBC) Generium Basic Information, Manufacturing Base and Competitors
Table 49. The International Biotechnology Center (IBC) Generium Major Business
Table 50. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product and Services
Table 51. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. The International Biotechnology Center (IBC) Generium Recent Developments/Updates
Table 53. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Manufacturer (2019-2024) & (K Pcs)
Table 54. Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturer (2019-2024) & (USD Million)
Table 55. Global Granulomatosis with Polyangiitis Drug Average Price by Manufacturer (2019-2024) & (USD/Pcs)
Table 56. Market Position of Manufacturers in Granulomatosis with Polyangiitis Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 57. Head Office and Granulomatosis with Polyangiitis Drug Production Site of Key Manufacturer
Table 58. Granulomatosis with Polyangiitis Drug Market: Company Product Type Footprint
Table 59. Granulomatosis with Polyangiitis Drug Market: Company Product Application Footprint
Table 60. Granulomatosis with Polyangiitis Drug New Market Entrants and Barriers to Market Entry
Table 61. Granulomatosis with Polyangiitis Drug Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2019-2024) & (K Pcs)
Table 63. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2025-2030) & (K Pcs)
Table 64. Global Granulomatosis with Polyangiitis Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 65. Global Granulomatosis with Polyangiitis Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 66. Global Granulomatosis with Polyangiitis Drug Average Price by Region (2019-2024) & (USD/Pcs)
Table 67. Global Granulomatosis with Polyangiitis Drug Average Price by Region (2025-2030) & (USD/Pcs)
Table 68. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
Table 69. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2025-2030) & (K Pcs)
Table 70. Global Granulomatosis with Polyangiitis Drug Consumption Value by Type (2019-2024) & (USD Million)
Table 71. Global Granulomatosis with Polyangiitis Drug Consumption Value by Type (2025-2030) & (USD Million)
Table 72. Global Granulomatosis with Polyangiitis Drug Average Price by Type (2019-2024) & (USD/Pcs)
Table 73. Global Granulomatosis with Polyangiitis Drug Average Price by Type (2025-2030) & (USD/Pcs)
Table 74. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
Table 75. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
Table 76. Global Granulomatosis with Polyangiitis Drug Consumption Value by Application (2019-2024) & (USD Million)
Table 77. Global Granulomatosis with Polyangiitis Drug Consumption Value by Application (2025-2030) & (USD Million)
Table 78. Global Granulomatosis with Polyangiitis Drug Average Price by Application (2019-2024) & (USD/Pcs)
Table 79. Global Granulomatosis with Polyangiitis Drug Average Price by Application (2025-2030) & (USD/Pcs)
Table 80. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
Table 81. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2025-2030) & (K Pcs)
Table 82. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
Table 83. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
Table 84. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2024) & (K Pcs)
Table 85. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2025-2030) & (K Pcs)
Table 86. North America Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 87. North America Granulomatosis with Polyangiitis Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 88. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
Table 89. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2025-2030) & (K Pcs)
Table 90. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
Table 91. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
Table 92. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2024) & (K Pcs)
Table 93. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2025-2030) & (K Pcs)
Table 94. Europe Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 95. Europe Granulomatosis with Polyangiitis Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 96. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
Table 97. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2025-2030) & (K Pcs)
Table 98. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
Table 99. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
Table 100. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2019-2024) & (K Pcs)
Table 101. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2025-2030) & (K Pcs)
Table 102. Asia-Pacific Granulomatosis with Polyangiitis Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 103. Asia-Pacific Granulomatosis with Polyangiitis Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 104. South America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
Table 105. South America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2025-2030) & (K Pcs)
Table 106. South America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
Table 107. South America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
Table 108. South America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2024) & (K Pcs)
Table 109. South America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2025-2030) & (K Pcs)
Table 110. South America Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 111. South America Granulomatosis with Polyangiitis Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 112. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
Table 113. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2025-2030) & (K Pcs)
Table 114. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
Table 115. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
Table 116. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2019-2024) & (K Pcs)
Table 117. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2025-2030) & (K Pcs)
Table 118. Middle East & Africa Granulomatosis with Polyangiitis Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 119. Middle East & Africa Granulomatosis with Polyangiitis Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 120. Granulomatosis with Polyangiitis Drug Raw Material
Table 121. Key Manufacturers of Granulomatosis with Polyangiitis Drug Raw Materials
Table 122. Granulomatosis with Polyangiitis Drug Typical Distributors
Table 123. Granulomatosis with Polyangiitis Drug Typical Customers
Table 1. Global Granulomatosis with Polyangiitis Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Granulomatosis with Polyangiitis Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Bionovis SA Basic Information, Manufacturing Base and Competitors
Table 4. Bionovis SA Major Business
Table 5. Bionovis SA Granulomatosis with Polyangiitis Drug Product and Services
Table 6. Bionovis SA Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Bionovis SA Recent Developments/Updates
Table 8. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 9. Bristol-Myers Squibb Company Major Business
Table 10. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product and Services
Table 11. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Bristol-Myers Squibb Company Recent Developments/Updates
Table 13. ChemoCentryx Inc Basic Information, Manufacturing Base and Competitors
Table 14. ChemoCentryx Inc Major Business
Table 15. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product and Services
Table 16. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. ChemoCentryx Inc Recent Developments/Updates
Table 18. Coherus BioSciences Inc Basic Information, Manufacturing Base and Competitors
Table 19. Coherus BioSciences Inc Major Business
Table 20. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product and Services
Table 21. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Coherus BioSciences Inc Recent Developments/Updates
Table 23. Genor BioPharma Co Ltd Basic Information, Manufacturing Base and Competitors
Table 24. Genor BioPharma Co Ltd Major Business
Table 25. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product and Services
Table 26. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Genor BioPharma Co Ltd Recent Developments/Updates
Table 28. GlaxoSmithKline Plc Basic Information, Manufacturing Base and Competitors
Table 29. GlaxoSmithKline Plc Major Business
Table 30. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product and Services
Table 31. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. GlaxoSmithKline Plc Recent Developments/Updates
Table 33. Iltoo Pharma Basic Information, Manufacturing Base and Competitors
Table 34. Iltoo Pharma Major Business
Table 35. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product and Services
Table 36. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Iltoo Pharma Recent Developments/Updates
Table 38. Panacea Biotec Ltd Basic Information, Manufacturing Base and Competitors
Table 39. Panacea Biotec Ltd Major Business
Table 40. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product and Services
Table 41. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Panacea Biotec Ltd Recent Developments/Updates
Table 43. Sandoz International GmbH Basic Information, Manufacturing Base and Competitors
Table 44. Sandoz International GmbH Major Business
Table 45. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product and Services
Table 46. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Sandoz International GmbH Recent Developments/Updates
Table 48. The International Biotechnology Center (IBC) Generium Basic Information, Manufacturing Base and Competitors
Table 49. The International Biotechnology Center (IBC) Generium Major Business
Table 50. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product and Services
Table 51. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. The International Biotechnology Center (IBC) Generium Recent Developments/Updates
Table 53. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Manufacturer (2019-2024) & (K Pcs)
Table 54. Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturer (2019-2024) & (USD Million)
Table 55. Global Granulomatosis with Polyangiitis Drug Average Price by Manufacturer (2019-2024) & (USD/Pcs)
Table 56. Market Position of Manufacturers in Granulomatosis with Polyangiitis Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 57. Head Office and Granulomatosis with Polyangiitis Drug Production Site of Key Manufacturer
Table 58. Granulomatosis with Polyangiitis Drug Market: Company Product Type Footprint
Table 59. Granulomatosis with Polyangiitis Drug Market: Company Product Application Footprint
Table 60. Granulomatosis with Polyangiitis Drug New Market Entrants and Barriers to Market Entry
Table 61. Granulomatosis with Polyangiitis Drug Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2019-2024) & (K Pcs)
Table 63. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2025-2030) & (K Pcs)
Table 64. Global Granulomatosis with Polyangiitis Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 65. Global Granulomatosis with Polyangiitis Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 66. Global Granulomatosis with Polyangiitis Drug Average Price by Region (2019-2024) & (USD/Pcs)
Table 67. Global Granulomatosis with Polyangiitis Drug Average Price by Region (2025-2030) & (USD/Pcs)
Table 68. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
Table 69. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2025-2030) & (K Pcs)
Table 70. Global Granulomatosis with Polyangiitis Drug Consumption Value by Type (2019-2024) & (USD Million)
Table 71. Global Granulomatosis with Polyangiitis Drug Consumption Value by Type (2025-2030) & (USD Million)
Table 72. Global Granulomatosis with Polyangiitis Drug Average Price by Type (2019-2024) & (USD/Pcs)
Table 73. Global Granulomatosis with Polyangiitis Drug Average Price by Type (2025-2030) & (USD/Pcs)
Table 74. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
Table 75. Global Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
Table 76. Global Granulomatosis with Polyangiitis Drug Consumption Value by Application (2019-2024) & (USD Million)
Table 77. Global Granulomatosis with Polyangiitis Drug Consumption Value by Application (2025-2030) & (USD Million)
Table 78. Global Granulomatosis with Polyangiitis Drug Average Price by Application (2019-2024) & (USD/Pcs)
Table 79. Global Granulomatosis with Polyangiitis Drug Average Price by Application (2025-2030) & (USD/Pcs)
Table 80. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
Table 81. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2025-2030) & (K Pcs)
Table 82. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
Table 83. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
Table 84. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2024) & (K Pcs)
Table 85. North America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2025-2030) & (K Pcs)
Table 86. North America Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 87. North America Granulomatosis with Polyangiitis Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 88. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
Table 89. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2025-2030) & (K Pcs)
Table 90. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
Table 91. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
Table 92. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2024) & (K Pcs)
Table 93. Europe Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2025-2030) & (K Pcs)
Table 94. Europe Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 95. Europe Granulomatosis with Polyangiitis Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 96. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
Table 97. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2025-2030) & (K Pcs)
Table 98. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
Table 99. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
Table 100. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2019-2024) & (K Pcs)
Table 101. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2025-2030) & (K Pcs)
Table 102. Asia-Pacific Granulomatosis with Polyangiitis Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 103. Asia-Pacific Granulomatosis with Polyangiitis Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 104. South America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
Table 105. South America Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2025-2030) & (K Pcs)
Table 106. South America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
Table 107. South America Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
Table 108. South America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2019-2024) & (K Pcs)
Table 109. South America Granulomatosis with Polyangiitis Drug Sales Quantity by Country (2025-2030) & (K Pcs)
Table 110. South America Granulomatosis with Polyangiitis Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 111. South America Granulomatosis with Polyangiitis Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 112. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2019-2024) & (K Pcs)
Table 113. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Type (2025-2030) & (K Pcs)
Table 114. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2019-2024) & (K Pcs)
Table 115. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Application (2025-2030) & (K Pcs)
Table 116. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2019-2024) & (K Pcs)
Table 117. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity by Region (2025-2030) & (K Pcs)
Table 118. Middle East & Africa Granulomatosis with Polyangiitis Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 119. Middle East & Africa Granulomatosis with Polyangiitis Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 120. Granulomatosis with Polyangiitis Drug Raw Material
Table 121. Key Manufacturers of Granulomatosis with Polyangiitis Drug Raw Materials
Table 122. Granulomatosis with Polyangiitis Drug Typical Distributors
Table 123. Granulomatosis with Polyangiitis Drug Typical Customers
LIST OF FIGURES
Figure 1. Granulomatosis with Polyangiitis Drug Picture
Figure 2. Global Granulomatosis with Polyangiitis Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Type in 2023
Figure 4. Benralizumab Examples
Figure 5. Avacopan Examples
Figure 6. Rituximab Biosimilar Examples
Figure 7. Others Examples
Figure 8. Global Granulomatosis with Polyangiitis Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 9. Global Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Application in 2023
Figure 10. Hospital Examples
Figure 11. Clinic Examples
Figure 12. Others Examples
Figure 13. Global Granulomatosis with Polyangiitis Drug Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global Granulomatosis with Polyangiitis Drug Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Granulomatosis with Polyangiitis Drug Sales Quantity (2019-2030) & (K Pcs)
Figure 16. Global Granulomatosis with Polyangiitis Drug Average Price (2019-2030) & (USD/Pcs)
Figure 17. Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Manufacturer in 2023
Figure 18. Global Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Manufacturer in 2023
Figure 19. Producer Shipments of Granulomatosis with Polyangiitis Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 20. Top 3 Granulomatosis with Polyangiitis Drug Manufacturer (Consumption Value) Market Share in 2023
Figure 21. Top 6 Granulomatosis with Polyangiitis Drug Manufacturer (Consumption Value) Market Share in 2023
Figure 22. Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Region (2019-2030)
Figure 23. Global Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Region (2019-2030)
Figure 24. North America Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030) & (USD Million)
Figure 25. Europe Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030) & (USD Million)
Figure 26. Asia-Pacific Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030) & (USD Million)
Figure 27. South America Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030) & (USD Million)
Figure 28. Middle East & Africa Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030) & (USD Million)
Figure 29. Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2019-2030)
Figure 30. Global Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Type (2019-2030)
Figure 31. Global Granulomatosis with Polyangiitis Drug Average Price by Type (2019-2030) & (USD/Pcs)
Figure 32. Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2019-2030)
Figure 33. Global Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Application (2019-2030)
Figure 34. Global Granulomatosis with Polyangiitis Drug Average Price by Application (2019-2030) & (USD/Pcs)
Figure 35. North America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2019-2030)
Figure 36. North America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2019-2030)
Figure 37. North America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Country (2019-2030)
Figure 38. North America Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Country (2019-2030)
Figure 39. United States Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Canada Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Mexico Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 42. Europe Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2019-2030)
Figure 43. Europe Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2019-2030)
Figure 44. Europe Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Country (2019-2030)
Figure 45. Europe Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Country (2019-2030)
Figure 46. Germany Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. France Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. United Kingdom Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Russia Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Italy Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2019-2030)
Figure 52. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2019-2030)
Figure 53. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Region (2019-2030)
Figure 54. Asia-Pacific Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Region (2019-2030)
Figure 55. China Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Japan Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Korea Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. India Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Southeast Asia Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. Australia Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. South America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2019-2030)
Figure 62. South America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2019-2030)
Figure 63. South America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Country (2019-2030)
Figure 64. South America Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Country (2019-2030)
Figure 65. Brazil Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. Argentina Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 67. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2019-2030)
Figure 68. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2019-2030)
Figure 69. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Region (2019-2030)
Figure 70. Middle East & Africa Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Region (2019-2030)
Figure 71. Turkey Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Egypt Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. Saudi Arabia Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. South Africa Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. Granulomatosis with Polyangiitis Drug Market Drivers
Figure 76. Granulomatosis with Polyangiitis Drug Market Restraints
Figure 77. Granulomatosis with Polyangiitis Drug Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Granulomatosis with Polyangiitis Drug in 2023
Figure 80. Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
Figure 81. Granulomatosis with Polyangiitis Drug Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
Figure 1. Granulomatosis with Polyangiitis Drug Picture
Figure 2. Global Granulomatosis with Polyangiitis Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Type in 2023
Figure 4. Benralizumab Examples
Figure 5. Avacopan Examples
Figure 6. Rituximab Biosimilar Examples
Figure 7. Others Examples
Figure 8. Global Granulomatosis with Polyangiitis Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 9. Global Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Application in 2023
Figure 10. Hospital Examples
Figure 11. Clinic Examples
Figure 12. Others Examples
Figure 13. Global Granulomatosis with Polyangiitis Drug Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global Granulomatosis with Polyangiitis Drug Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Granulomatosis with Polyangiitis Drug Sales Quantity (2019-2030) & (K Pcs)
Figure 16. Global Granulomatosis with Polyangiitis Drug Average Price (2019-2030) & (USD/Pcs)
Figure 17. Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Manufacturer in 2023
Figure 18. Global Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Manufacturer in 2023
Figure 19. Producer Shipments of Granulomatosis with Polyangiitis Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 20. Top 3 Granulomatosis with Polyangiitis Drug Manufacturer (Consumption Value) Market Share in 2023
Figure 21. Top 6 Granulomatosis with Polyangiitis Drug Manufacturer (Consumption Value) Market Share in 2023
Figure 22. Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Region (2019-2030)
Figure 23. Global Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Region (2019-2030)
Figure 24. North America Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030) & (USD Million)
Figure 25. Europe Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030) & (USD Million)
Figure 26. Asia-Pacific Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030) & (USD Million)
Figure 27. South America Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030) & (USD Million)
Figure 28. Middle East & Africa Granulomatosis with Polyangiitis Drug Consumption Value (2019-2030) & (USD Million)
Figure 29. Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2019-2030)
Figure 30. Global Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Type (2019-2030)
Figure 31. Global Granulomatosis with Polyangiitis Drug Average Price by Type (2019-2030) & (USD/Pcs)
Figure 32. Global Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2019-2030)
Figure 33. Global Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Application (2019-2030)
Figure 34. Global Granulomatosis with Polyangiitis Drug Average Price by Application (2019-2030) & (USD/Pcs)
Figure 35. North America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2019-2030)
Figure 36. North America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2019-2030)
Figure 37. North America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Country (2019-2030)
Figure 38. North America Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Country (2019-2030)
Figure 39. United States Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Canada Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Mexico Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 42. Europe Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2019-2030)
Figure 43. Europe Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2019-2030)
Figure 44. Europe Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Country (2019-2030)
Figure 45. Europe Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Country (2019-2030)
Figure 46. Germany Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. France Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. United Kingdom Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Russia Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Italy Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2019-2030)
Figure 52. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2019-2030)
Figure 53. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Region (2019-2030)
Figure 54. Asia-Pacific Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Region (2019-2030)
Figure 55. China Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Japan Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Korea Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. India Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Southeast Asia Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. Australia Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. South America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2019-2030)
Figure 62. South America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2019-2030)
Figure 63. South America Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Country (2019-2030)
Figure 64. South America Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Country (2019-2030)
Figure 65. Brazil Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. Argentina Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 67. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Type (2019-2030)
Figure 68. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Application (2019-2030)
Figure 69. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Quantity Market Share by Region (2019-2030)
Figure 70. Middle East & Africa Granulomatosis with Polyangiitis Drug Consumption Value Market Share by Region (2019-2030)
Figure 71. Turkey Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Egypt Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. Saudi Arabia Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. South Africa Granulomatosis with Polyangiitis Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. Granulomatosis with Polyangiitis Drug Market Drivers
Figure 76. Granulomatosis with Polyangiitis Drug Market Restraints
Figure 77. Granulomatosis with Polyangiitis Drug Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Granulomatosis with Polyangiitis Drug in 2023
Figure 80. Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
Figure 81. Granulomatosis with Polyangiitis Drug Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
